About / the reading desk
About Reviews Sermorelin
An independent editorial reading of the published sermorelin literature — who we are, what we do, and what we deliberately are not.
What this site is
Reviews Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin and the broader GHRH(1-29) record. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The model is simple and deliberately narrow: read the published studies, report what they actually measured, and cite every quantitative claim to its source. The retro reading-desk framing is just that — a way of presenting the literature as a tidy stack of titled records — not a claim to any laboratory, pharmacy, or practice.
What 'reviews' means here
The word "reviews" in this site's name is editorial, not commercial. It signals a research-literature-review register — a reviewer's reading of the published record — not product reviews, ratings, or a place to buy anything. There is no storefront here, no ordering, no sourcing, and no endorsement of any vendor. "Reviews" describes the position the publisher occupies relative to the studies: someone reading the literature and reporting it plainly.
We hold a clear line between describing research and recommending action. The studies summarized here include a former approved pediatric indication and adult endocrine research; we report those findings and their regulatory history factually, and we give no dosing recommendations and no medical guidance. Where the evidence is strong, we say so; where marketing has outrun the data — as with anti-aging claims for sermorelin — we say that too.
Our sourcing standard
Every figure on this site is drawn from a named study in the peer-reviewed literature — PubMed-indexed journals, controlled trials, and recognized reviews — and listed on the references page with a resolvable DOI or PubMed link. When a finding comes from a related GHRH analog rather than sermorelin itself, we name the distinction in the text rather than blurring it; this is a recurring trap in popular sermorelin coverage, where tesamorelin's body-composition results quietly become "sermorelin benefits." We do not extrapolate beyond what a study reported, and we do not present hypothesis-generating or computational signals as clinical evidence. The references page is the audit trail; if a claim is not traceable there, it does not belong in the body.
We also try to be honest about the shape of the record, not just its highlights. Sermorelin's strongest data are decades old and pediatric; its adult and anti-aging evidence is thinner and, in places, cautioned against by the same literature. A reading desk worth the name reports the gaps and the caveats with the same plainness as the headline numbers, which is what we aim to do here.